FibroBiologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 16.49 million compared to USD 5.12 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.99 USD | +4.44% | +9.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 373M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- FBLG Stock
- News FibroBiologics, Inc.
- FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023